Navigation Links
China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
Date:10/18/2011

HARBIN, China, Oct. 18, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the board increased the number of directors on the board of directors to five at its annual board meeting and appointed Mr. Zack Zibing Pan to its Board of Directors, effective October 15, 2011. Mr. Pan will serve as an independent director and chairman of the Audit Committee, and a member of the Nomination and Compensation Committee.

Mr. Pan is currently the Chief Financial Officer of Biostar Pharmaceuticals, Inc., a Maryland company operated in China through its wholly owned subsidiary and controlled affiliate and listed on the NASDAQ ("Biostar"). From December 30, 2009 until April 2011, Mr. Pan served as a director of Biostar and also as the chairman of Biostar's audit committee. Mr. Pan was chief financial officer of China Education Alliance, Inc., a provider of quality educational resources in China that is listed on NYSE, to which he was appointed in August 2009. Prior to that position, Mr. Pan was an audit manager with Eide Bailly CPAs & Business Advisors at its Oklahoma City office. Mr. Pan had been working at Eide Bailly since September 2005. Mr. Pan spent seven years as a statistical analyst and economist with the State of Oklahoma. Mr. Pan has also served as a loan project officer for Asian Development Bank Loan Management Office in Anhui, China and as an associate professor at Anhui University, China.

Mr. Pan is a Certified Public Accountant, certified by the Oklahoma State Board of Accountancy. He is also a member of the American Institute of Certified Public Accountants (AICPA) and the Oklahoma Society of Certified Public Accountants (OSCPA). Mr. Pan graduat
'/>"/>

SOURCE China Botanic Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 19, 2011
2. Industrial Biotechnology China News 1109 - Annual Subscription
3. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
4. China Cord Blood Corporation Files Its Annual Report on Form 20-F
5. China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results
6. Industrial Biotechnology China News 1108
7. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012
8. China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results
9. Industrial Biotechnology China News 1106
10. China Agri-Business Acquired Management and Operation Rights of Shaanxi Qinfeng Agrochemical Inc. in Xian, China
11. China-Biotics, Inc. Receives NASDAQ Delisting Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 A new ... it easier for research institutions to learn how Apple’s ... data. , The timing is ideal since Apple made ... Research Kit is an open-source framework for developing medical ... provides a way for researchers to collect secure clinical ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, today ... has been added as a clinical trial site for ... patients with refractory glioblastoma multiforme (GBM), the most common ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... BioPharma Corp. (TSX, FSE: "HBP") today announced that John ... the BioFinance 2009 Investor Conference at 3:00 p.m. EDT ... Toronto. Mr. Docherty will provide an overview of ... its current product development programs, L-DOS47 and Topical Interferon ...
... Medical Corp (TSX: MS), a leading developer in the treatment of multiple ... present at BioFinance 2009 in Toronto., WHEN: Wednesday ... Eaton Centre Hotel (Trinity V room), ... Toronto, ON, About BioFinance ...
... Ltd, announced,today that it has been engaged by ... in,divesting its world class research centre, the IRBM, ... pharmaceutical,transactions experience in the healthcare and investment business ... and biological,discovery centre. IRBM has an outstanding record ...
Cached Biology Technology:Helix BioPharma to Present at the BioFinance 2009 Conference 2BioMS Medical to present at BioFinance 2009 2Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM 2
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... leading global STM publishers, has entered a publishing partnership ... Estuaries and Coasts. Appearing six times a year, ... on and management of estuarine and coastal ecosystems. ... 2008. The partnership will be officially announced at ...
... had megadroughts more extreme and widespread than any previously known ... now-lush tropical Africa was an arid scrubland during the early ... Africa and the evolution of fishes in Africa,s Great Lakes. ... the world, acts as a rain gauge," said lead scientist ...
... by an Indiana University environmental science professor and several ... corn has the potential to harm aquatic ecosystems. The ... journal Proceedings of the National Academies of Sciences ... assistant professor in the IU School of Public and ...
Cached Biology News:Estuarine Research Federation chooses Springer as publishing partner 2Newfound ancient African megadroughts may have driven the evolution of humans and fishes 2Newfound ancient African megadroughts may have driven the evolution of humans and fishes 3Newfound ancient African megadroughts may have driven the evolution of humans and fishes 4Study shows genetically engineered corn could affect aquatic ecosystems 2Study shows genetically engineered corn could affect aquatic ecosystems 3
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
...
Biology Products: